Cargando…
Environment-mediated drug resistance in Bcr/Abl-positive acute lymphoblastic leukemia
Although cure rates for acute lymphoblastic leukemia (ALL) have increased, development of resistance to drugs and patient relapse are common. The environment in which the leukemia cells are present during the drug treatment is known to provide significant survival benefit. Here, we have modeled this...
Autores principales: | Feldhahn, Niklas, Arutyunyan, Anna, Stoddart, Sonia, Zhang, Bin, Schmidhuber, Sabine, Yi, Sun-Ju, Kim, Yong-mi, Groffen, John, Heisterkamp, Nora |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Landes Bioscience
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3429566/ https://www.ncbi.nlm.nih.gov/pubmed/22934254 http://dx.doi.org/10.4161/onci.20249 |
Ejemplares similares
-
Development of resistance to dasatinib in Bcr/Abl-positive acute lymphoblastic leukemia
por: Fei, Fei, et al.
Publicado: (2010) -
Nilotinib treatment in mouse models of P190 Bcr/Abl lymphoblastic leukemia
por: Kaur, Pavinder, et al.
Publicado: (2007) -
Treatment of human pre-B acute lymphoblastic leukemia with the Aurora kinase inhibitor PHA-739358 (Danusertib)
por: Fei, Fei, et al.
Publicado: (2012) -
Lack of Bcr and Abr Promotes Hypoxia-Induced Pulmonary Hypertension in Mice
por: Yu, Min, et al.
Publicado: (2012) -
Transcriptomic classes of BCR-ABL1 lymphoblastic leukemia
por: Kim, Jaeseung C., et al.
Publicado: (2023)